Emcure plans Zuventus, Emcutix merger as domestic sales rise

Emcure will merge Zuventus and Emcutix with its holding company while domestic revenue rose 12.0% year on year to Rs 1,155.3 crore in the second quarter of financial year 2027, or Q2FY27. Emcure said the restructuring supports its One Emcure vision to simplify the group holding structure and create synergies in backend operations and corporate functions.

Why is Emcure merging Zuventus and Emcutix?

Emcure is merging Zuventus and Emcutix with the holding company to simplify its group holding structure and seek synergies in backend operations and corporate functions. The Q2FY27 presentation describes the transaction as part of the One Emcure vision, but does not disclose a transaction date, consideration, regulatory timetable or expected financial effect.

The proposal follows sequential improvement at Zuventus in Q2FY27. Emcure said anchor brands Zostum and Bevon grew 34% and 17%, respectively, year on year in IQVIA September 2026 data. The proposed simplification therefore accompanies improved domestic brand traction rather than being presented as a stand-alone cost programme.

How fast did Emcure's domestic business grow in Q2FY27?

Emcure's domestic business grew 12.0% year on year to Rs 1,155.3 crore in Q2FY27, accelerating from 10% growth in Q1FY27. Domestic revenue also increased 5.5% from Rs 1,095.3 crore in Q1FY27, while first-half financial year 2027, or H1FY27, domestic revenue rose 11.1% to Rs 2,250.6 crore from Rs 2,026.1 crore in H1FY26.

Domestic sales made up 41.0% of Emcure's Q2FY27 revenue mix, against 59.0% for international sales combined. Total revenue from operations grew 24.3% to Rs 2,820.5 crore because international revenue increased 34.5% to Rs 1,665.2 crore. Domestic growth was therefore positive and faster than the preceding quarter's 10%, but below the international growth rate in Q2FY27.

Which products supported Emcure's domestic growth?

Emcure attributed Q2FY27 domestic growth to women's health, cardio-metabolics and central nervous system, or CNS, therapies. IQVIA September 2026 data showed year-on-year growth of 39% for Orofer XT and Orofer FCM, 64% for Rosuvas EZ, 18% for Vylda and 43% for Tenectase.

Poviztra recorded more than 23% quarter-on-quarter growth in Q2FY27, adding to the indicators of improved portfolio traction. Emcure did not disclose revenue for individual brands, so the reported brand-growth percentages do not show each product's contribution to quarterly domestic revenue of Rs 1,155.3 crore.

Management said it expects continued growth through the full year as its strengthened team and portfolio gain traction. That is management's outlook rather than a quantified target, as Emcure did not disclose a full-year domestic-revenue objective, expected market-share gain or merger timetable in the Q2FY27 presentation.

How did domestic growth fit Emcure's wider Q2FY27 performance?

Emcure reported earnings before interest, tax, depreciation and amortisation, or EBITDA, of Rs 574.8 crore in Q2FY27, up 30.9% year on year, while its EBITDA margin rose 103 basis points to 20.4%. Profit after tax increased 29.3% to Rs 325.1 crore and the profit-after-tax margin rose 45 basis points to 11.5%.

Gross profit margin declined 131 basis points year on year to 59.5% in Q2FY27 from 60.8% in Q2FY26. Sequentially, gross profit margin increased 108 basis points from 58.4% in Q1FY27, while EBITDA margin rose 69 basis points from 19.7%.

Capital expenditure was Rs 164.8 crore in Q2FY27, compared with Rs 75.2 crore in Q2FY26. H1FY27 capital expenditure was Rs 281.6 crore, against Rs 170.0 crore in H1FY26, while research and development spending was Rs 111.0 crore in Q2FY27, equal to 3.9% of revenue. The presentation does not allocate these amounts between domestic brands, the merger initiative and international operations.

What balance-sheet factors matter for Emcure's plan?

Emcure reported net debt of Rs 1,317.1 crore at September 30, 2026, up from Rs 1,053.8 crore at March 31, 2026, while net debt to trailing 12-month EBITDA remained 0.6 times. Emcure attributed the rise in debt to the Mantra earnout and Gennova consolidation payments.

Gross debt was Rs 1,467.3 crore and cash and liquid investments were Rs 150.2 crore at September 30, 2026. Return on capital employed was 24.9% at that date, compared with 23.7% at March 31, 2026 and 22.0% at March 31, 2025. Emcure has not quantified cost savings, integration charges or capital effects from combining Zuventus and Emcutix with the holding company.

Conclusion

Emcure is pairing the proposed simplification of Zuventus and Emcutix with domestic revenue momentum, which reached Rs 1,155.3 crore in Q2FY27 after 12.0% year-on-year growth. Women's health, cardio-metabolics and CNS brands were cited as contributors, while international revenue grew faster at 34.5% to Rs 1,665.2 crore.

The next disclosures to watch are merger terms, implementation timing and any quantified backend or corporate-function synergies, none of which appeared in the Q2FY27 presentation. Management expects continued full-year growth from the strengthened domestic team and portfolio, while later results will show whether domestic growth continues beyond the 11.1% reported for H1FY27.